Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
Yiyi Yan, Anagha Kumar, Heidi D. Finnes, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 195

Showing 1-25 of 195 citing articles:

Head and neck cancer
Mayur D. Mody, James W. Rocco, Sue S. Yom, et al.
The Lancet (2021) Vol. 398, Iss. 10318, pp. 2289-2299
Closed Access | Times Cited: 285
The pro-tumorigenic host response to cancer therapies
Yuval Shaked
Nature reviews. Cancer (2019) Vol. 19, Iss. 12, pp. 667-685
Closed Access | Times Cited: 164
Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy
Yuka Igarashi, Tetsuro Sasada
Journal of Immunology Research (2020) Vol. 2020, pp. 1-13
Open Access | Times Cited: 152
Immunotherapy for glioblastoma: the promise of combination strategies
Mathilde Bausart, Véronique Préat, Alessio Malfanti
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 140
Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity
Suah Yang, Man Kyu Shim, Woo Jun Kim, et al.
Biomaterials (2021) Vol. 272, pp. 120791-120791
Closed Access | Times Cited: 110
Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Benjamin Himes, Philipp Geiger, Katayoun Ayasoufi, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 106
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
Haiping Jiang, Xiongfei Yu, Ning Li, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 3, pp. e003635-e003635
Open Access | Times Cited: 76
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 55
Doxorubicin prodrug-based nanomedicines for the treatment of cancer
Haibo Zhao, Jing Yu, Renshuai Zhang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115612-115612
Closed Access | Times Cited: 51
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Pankaj Garg, Jyoti Malhotra, Prakash Kulkarni, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2478-2478
Open Access | Times Cited: 33
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
Yeon Hee Park, Samir Lal, Jeong Eon Lee, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 137
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
James W. Opzoomer, Dominika Sosnowska, Joanne E. Anstee, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 127
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Romain-David Seban, Laura Mezquita, Arnaud Berenbaum, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2019) Vol. 47, Iss. 5, pp. 1147-1157
Closed Access | Times Cited: 112
Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis
Li Sun, Qianqian Wang, Bin Chen, et al.
Cell Death and Disease (2018) Vol. 9, Iss. 9
Open Access | Times Cited: 110
Immunoadjuvants for cancer immunotherapy: A review of recent developments
Asmita Banstola, Jee‐Heon Jeong, Simmyung Yook
Acta Biomaterialia (2020) Vol. 114, pp. 16-30
Closed Access | Times Cited: 107
STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects
Milad Ashrafizadeh, Ali Zarrabi, Sima Orouei, et al.
Biology (2020) Vol. 9, Iss. 6, pp. 126-126
Open Access | Times Cited: 97
Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
Zhe Fu, Alexandra M. Mowday, Jeff B. Smaill, et al.
Cells (2021) Vol. 10, Iss. 5, pp. 1006-1006
Open Access | Times Cited: 82
Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis
Li Sun, Chao‐Yuan Huang, Miaolin Zhu, et al.
Theranostics (2020) Vol. 10, Iss. 26, pp. 11950-11962
Open Access | Times Cited: 78
BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes
Yu‐Li Chen, Han-Wei Lin, C. L. Chien, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 77
Metformin and cancer immunity
Ruixia Ma, Bin Yi, Adam I. Riker, et al.
Acta Pharmacologica Sinica (2020) Vol. 41, Iss. 11, pp. 1403-1409
Open Access | Times Cited: 77
Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine
Afshin Derakhshani, Shahryar Hashemzadeh, Zahra Asadzadeh, et al.
Cancers (2021) Vol. 13, Iss. 10, pp. 2414-2414
Open Access | Times Cited: 72
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
Shima Makaremi, Zahra Asadzadeh, Nima Hemmat, et al.
Biomedicines (2021) Vol. 9, Iss. 9, pp. 1075-1075
Open Access | Times Cited: 67
Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells
Brandon J. Burbach, Stephen O’Flanagan, Qi Shao, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 66
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
Dan You, Stephen Hillerman, Gregory Locke, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 1, pp. e001402-e001402
Open Access | Times Cited: 61
Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy
DaeYong Lee, Kristin Huntoon, Yifan Wang, et al.
Advanced Materials (2021) Vol. 33, Iss. 27
Closed Access | Times Cited: 60
Page 1 - Next Page

Scroll to top